Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Assets: 2020-2024

Historic Current Assets for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Dec 2024 value amounting to $11.8 million.

  • Insight Molecular Diagnostics' Current Assets rose 346.25% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 346.25%. This contributed to the annual value of $11.8 million for FY2024, which is 9.92% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Current Assets stood at $11.8 million for FY2024, which was up 9.92% from $10.7 million recorded in FY2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Current Assets peaked at $39.1 million during FY2021, and registered a low of $9.2 million during FY2020.
  • Over the past 3 years, Insight Molecular Diagnostics' median Current Assets value was $11.8 million (recorded in 2024), while the average stood at $16.0 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Current Assets spiked by 324.27% in 2021, and later tumbled by 58.11% in 2023.
  • Yearly analysis of 5 years shows Insight Molecular Diagnostics' Current Assets stood at $9.2 million in 2020, then spiked by 324.27% to $39.1 million in 2021, then plummeted by 34.76% to $25.5 million in 2022, then crashed by 58.11% to $10.7 million in 2023, then rose by 9.92% to $11.8 million in 2024.